Evidence map›Paper›PMID 37109035›Full record

ArticleJournal of personalized medicine2023

Chlorogenic Acid Attenuates Doxorubicin-Induced Oxidative Stress and Markers of Apoptosis in Cardiomyocytes via Nrf2/HO-1 and Dityrosine Signaling.

Betul Cicek, Ahmet Hacimuftuoglu, Yesim Yeni, Betul Danisman, Mustafa Ozkaraca, Behzad Mokhtare, Mecit Kantarci, Marios Spanakis, Dragana Nikitovic, Georgios Lazopoulos and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Role of vitamins beyond vitamin DInternational journal of molecular medicine · 2024
    Review
  16. Review
  17. Article
  18. Composition ofMolecules (Basel, Switzerland) · 2023
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Betul CicekDepartment of Physiology, Faculty of Medicine, Erzincan Binali Yildirim University, 24100 Erzincan, Turkey.
Ahmet HacimuftuogluDepartment of Medical Pharmacology, Faculty of Medicine, Ataturk University, 25240 Erzurum, Turkey.
Yesim YeniDepartment of Medical Pharmacology, Faculty of Medicine, Malatya Turgut Ozal University, 44210 Malatya, Turkey.ORCID 0000-0002-6719-7077
Betul DanismanDepartment of Biophysics, Faculty of Medicine, Ataturk University, 25240 Erzurum, Turkey.
Mustafa OzkaracaDepartment of Pathology, Faculty of Veterinary, Sivas Cumhuriyet University, 58140 Sivas, Turkey.ORCID 0000-0002-6359-6249
Behzad MokhtareDepartment of Pathology, Faculty of Veterinary, Sivas Cumhuriyet University, 58140 Sivas, Turkey.
Mecit KantarciDepartment of Radiology, Faculty of Medicine, Ataturk University, 25240 Erzurum, Turkey.
Marios SpanakisDepartment of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, 71003 Heraklion, Greece.ORCID 0000-0003-2163-0653
Dragana NikitovicDragana Nikitovic, Laboratory of Histology-Embryology, School of Medicine, University of Crete, 71003 Heraklion, Greece.ORCID 0000-0003-3882-7399
Georgios LazopoulosDepartment of Cardiac Surgery, University General Hospital of Heraklion, Medical School, University of Crete, 71003 Heraklion, Greece.
Konstantinos TsarouhasDepartment of Cardiology, University General Hospital of Larissa, 41110 Larissa, Greece.ORCID 0000-0003-2651-3579
Aristidis TsatsakisDepartment of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, 71003 Heraklion, Greece.ORCID 0000-0003-3824-2462
Ali TaghizadehghalehjoughiDepartment of Medical Pharmacology, Faculty of Medicine, Bilecik Seyh Edebali University, 11230 Bilecik, Turkey.ORCID 0000-0002-3506-0324
University of Crete · GRAtatürk University · TRSivas Cumhuriyet Üniversitesi · TRBilecik Şeyh Edebali Üniversitesi · TRErzincan Binali Yıldırım University · TRTurgut Özal University · TRUniversity Hospital of Larissa · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Doxorubicin (DOX) is extensively used for cancer treatments; however, its clinical application is limited because of its cardiotoxic adverse effects. A combination of DOX and agents with cardioprotective properties is an effective strategy to ameliorate DOX-related cardiotoxicity. Polyphenolic compounds are ideal for the investigation of novel cardioprotective agents. Chlorogenic acid (CGA), an essential dietary polyphenol found in plants, has been previously reported to exert antioxidant, cardioprotective, and antiapoptotic properties. The current research evaluated CGA's in vivo cardioprotective properties in DOX-induced cardiotoxicity and the probable mechanisms underlying this protection. (2) Methods: CGA's cardioprotective properties were investigated in rats that were treated with CGA (100 mg/kg, p.o.) for fourteen days. The experimental model of cardiotoxicity was induced with a single intraperitoneal (15 mg/kg i.p.) injection of DOX on the 10th day. (3) Results: Treatment with CGA significantly improved the DOX-caused altered cardiac damage markers (LDH, CK-MB, and cTn-T), and a marked improvement in cardiac histopathological features accompanied this. DOX downregulated the expression of Nrf2/HO-1 signaling pathways, and the CGA reversed this effect. Consistently, caspase-3, an apoptotic-related marker, and dityrosine expression were suppressed, while Nrf2 and HO-1 expressions were elevated in the cardiac tissues of DOX-treated rats after treatment with the CGA. Furthermore, the recovery was confirmed by the downregulation of 8-OHdG and dityrosine (DT) expressions in immunohistochemical findings. (4) Conclusions: CGA demonstrated a considerable cardioprotective effect against DOX-induced cardiotoxicity. One of the possible mechanisms for these protective properties was the upregulation of the Nrf2/HO-1-dependent pathway and the downregulation of DT, which may ameliorate oxidative stress and cardiomyocyte apoptosis. These findings suggest that CGA may be cardioprotective, particularly in patients receiving DOX-based chemotherapy.

Indexed as

cardiotoxicitychlorogenic aciddoxorubicinNrf2/HO-1oxidative stress

Identifiers

PMID37109035
PMCPMC10140899
OpenAlexW4362733449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.